AMENDMENT TO AGREEMENT

EXHIBIT 10.15

AMENDMENT TO AGREEMENT

THIS AMENDMENT to that certain agreement entered into as of October 30 2006 (the “▇▇▇▇▇▇▇▇ Agreement”) by and between Optical Molecular Imaging, Inc., now known as ImmunoCellular Therapeutics, Ltd. (“ICT”) and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ (“▇▇▇▇▇▇▇▇”) (together, the “Parties”) is entered into by the Parties with reference to the following facts:

A. ICT and ▇▇▇▇▇▇▇▇ previously entered into the ▇▇▇▇▇▇▇▇ Agreement, specifying the terms and conditions under which ▇▇▇▇▇▇▇▇ would serve ICT as its President and Chief Operating Officer; and

B. ICT and ▇▇▇▇▇▇▇▇ wish to amend certain provisions of the ▇▇▇▇▇▇▇▇ Agreement.

NOW, THEREFORE, the parties agree as follows:

1. Paragraph 1 Amendment. Paragraph 1 of the ▇▇▇▇▇▇▇▇ Agreement is hereby amended by replacing the last sentence of Paragraph 1 with the following sentence:

“▇▇▇▇▇▇▇▇ shall perform the Services on a part-time basis through May 31, 2007, and commencing on June 1, 2007, on a full-time basis during the Company’s normal business hours.”

2. Paragraph 3.1 Amendment. Paragraph 3.1 of the ▇▇▇▇▇▇▇▇ Agreement is hereby amended by replacing the second sentence of Paragraph 3.1 with the following sentence:

As payment in full for the Services during the term of the Agreement, the Company shall grant to ▇▇▇▇▇▇▇▇ options to purchase 95,000 shares of the Company’s common stock (the “New Options”), which shall vest quarterly over the one-year term of this Agreement, and a salary of $2,000 per month, which shall increase to $2,500 per month immediately upon the Company signing the definitive License Agreement with Cedars-Sinai Medical Center and which shall increase to $10,000 per month effective as of June 1, 2007.

3. Continuation of ▇▇▇▇▇▇▇▇ Agreement. Except as modified above, all of the provisions of the ▇▇▇▇▇▇▇▇ Agreement, including the right of either of the Parties to terminate the ▇▇▇▇▇▇▇▇ Agreement without cause upon 30 days written notice, shall continue in full force and effect.

THIS AMENDMENT TO AGREEMENT, together with the ▇▇▇▇▇▇▇▇ Agreement as modified by this Amendment to Agreement, constitutes the entire agreement of ICT and ▇▇▇▇▇▇▇▇ pertaining to the subject matter of this Amendment to Agreement and the ▇▇▇▇▇▇▇▇ Agreement. This Amendment to Agreement may be executed in one or more counterparts, each of which is an original and all of which together constitute one and the same instrument.

IN WITNESS WHEREOF, ICT and ▇▇▇▇▇▇▇▇ have executed this Amendment to Agreement as of June 28, 2007.

						IMMUNOCELLULAR THERAPEUTICS, LTD.
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇						By:		/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇								▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
								Secretary

2